Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 68, Issue 4, 2009, Pages 546-551

  Jick, S S ^a   Choi, H ^b   Li, L ^a   Mclnnes, I B ^c   Sattar, N ^d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CIPROFIBRATE; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; ANTILIPEMIC AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DATA BASE; FEMALE; GENERAL PRACTICE; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; COMPARATIVE STUDY; MIDDLE AGED; RISK; STATISTICAL MODEL;

AGED; ANTILIPEMIC AGENTS; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK;

EID: 65249186450     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.091967     Document Type: Article

References (48)

1. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
2. 4S Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
4. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-26.
5. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-4.
6. Palinski W. New evidence for beneficial effects of statins unrelated to lipid lowering. Arterioscler Thromb Vasc Biol 2001;21:3-5.
7. Crisby M, Nordin-Fredricksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926- 33.
8. Kobashigawa JA, Katznelson S, Laks H, Johnson JA, Yeatman L, Wang XM, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-7.
9. Wenke K, Meiser B, Thiery J, Nagel D, von Scheidt W, Steinbeck G, et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation 1997;96:1398-402.
10. Mach F. Statins as immunomodulatory agents. Circulation 2004;109(21 suppl 1):II15-17.
11. Kobashigawa JA, Moriguchi JD, Laks H, Wener L, Hage A, Hamilton MA, et al. Tenyear follow-up of a randomized trial of pravastatin in heart transplant patients. J Heart Lung Transplant 2005;24:1736-40.
12. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31.
13. Rogers J, Shen Y. A perspective on inflammation in Alzheimer's disease. Ann NY Acad Sci 2000;924:132-5.
14. Weninger SC, Yankner BA. Inflammation and Alzheimer disease: the good, the bad, and the ugly. Nat Med 2001;7:527-8.
15. Sparrow CP, Burton CA, Hernandez M, Mundt S, Hassing H, Patel S, et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001;21:115-21.
16. Leung BP, Sattar N, Crilly A, Prach M, McCarey DW, Payne H, et al. A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol 2003;170:1524-30.
17. Barsante MM, Roffe E, Yokoro CM, Tafuri WL, Souza DG, Pinho V, et al. Antiinflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005;516:282-9.
18. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2006;33:463-71.
19. Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant 2006;21:337-44.
20. Yamagata T, Kinoshita K, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Effects of pravastatin in murine collagen-induced arthritis. Rheumatol Int 2007;27:631-9.
21. Chang LT, Sun CK, Chiang CH, Wu CJ, Chua S, Yip HK. Impact of simvastatin and losartan on antiinflammatory effect: in vitro study. J Cardiovasc Pharmacol 2007;49:20-6.
22. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebocontrolled trial. Lancet 2004;363:2015-21.
23. Garca Rodrguez L, Pérez Gutthan S. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharm 1998;45:419-25.
24. Jick H, Terris B, Derby L, Jick S. Further validation of information recorded on a general practitioner based computerized data resource in the United Kingdom. Pharmacoepidemiol Drug Saf 1992;1:347-9.
25. Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992;22:172-8.
26. Situnayake RD, Kitas G. Dyslipidemia and rheumatoid arthritis. Ann Rheum Dis 1997;56:341-2.
27. Kavanaugh A. Lipid profiles in patients with rheumatoid arthritis. Ann Rheum Dis 1998;57:175.
28. Yoo WH. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004;31:1746-53.
29. Dursunoglu D, Evrengul H, Polat B, Tanriverdi H, Cobankara V, Kaftan A, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005;25:241-5.
30. van Halm VP, Nielen MM, Nurmohamed MT, van Schaardenburg D, Reesink HW, Voskuyl AE, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007;66:184-8.
31. Ma DW. Lipid mediators in membrane rafts are important determinants of human health and disease. Appl Physiol Nutr Metab 2007;32:341-50.
32. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-8.
33. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 2001;103:357-62.
34. Katznelson S, Wilkinson AH, Kobashigawa JA, Wang XM, Chia D, Ozawa M. The effect of pravastatin on acute rejection after kidney transplantation-a pilot study. Transplantation 1996;61:1469-74.
35. Tuncer M, Suleymanlar G, Ersoy FF, Yakupoglu G. Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients. Transplant Proc 2000;32:622-5.
36. Poynter JN, Gruber SB, Higgins PD, Wang XM, Chia D, Ozawa M, et al. Statins and the risk of colorectal cancer. N Engl J Med 2005;352:2184-92.
37. Abeles AM, Pillinger MH. Statins as antiinflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 2006;54:393-407.
38. Palinski W, Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 2002;22:1745-50.
39. Yang CC, Jick SS, Testa MA. Who receives lipid-lowering drugs: the effects of comorbidities and patient characteristics on treatment initiation. Br J Clin Pharmacol 2003;55:288-98.
40. Hernandez Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, et al. Reproductive factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1990;1:285-91.
41. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997;40:1955-61.
42. Stolt P, Bengtsson C, Nordmark B, Lindblad S, Lundberg I, Klareskog L, et al, EIRA study group. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis 2003;62:835-41.
43. Olsson AR, Skogh T, Wingren G. Aetiological factors of importance for the development of rheumatoid arthritis. Scand J Rheumatol 2004;33:300-6.
44. Costenbader KH, Feskanich D, Mandl LA, Karlson EW. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am J Med 2006;119:503.e1-9.
45. Linos A, Worthington JW, O'Fallon WM, Kurland LT. The epidemiology of rheumatoid arthritis in Rochester, Minnesota: a study of incidence, prevalence, and mortality. Am J Epidemiol 1980;111:87-98.
46. Dugowson CE, Koepsell TD, Voigt LF, Bley L, Nelson JL, Daling JR. Rheumatoid arthritis in women. Incidence rates in group health cooperative, Seattle, Washington, 1987-1989. Arthritis Rheum 1991;34:1502-7.
47. Chan KW, Felson DT, Yood RA, Walker AM. Incidence of rheumatoid arthritis in central Massachusetts. Arthritis Rheum 1993;36:1691-6.
48. Chan KW, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37:814-20.